Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Pharmaceutical Business Review
Return to: PBR Home
Top Headlines

Pharmaceutical Business Review

Mylan introduces MyHep tablets in India to treat chronic hepatitis C Mylan Pharmaceuticals has introduced generic version of Sofosbuvir 400mg tablets in India under the brand name MyHep. Production & Manufacturing > Manufacturing > News
Dicerna gets FDA orphan drug status for DCR-PH1 to treat primary hyperoxaluria type 1 By PBR Staff Writer
Dicerna Pharmaceuticals has received orphan drug designation from the US Food and Drug Administration (FDA) for its therapeutic candidate, DCR-PH1, to treat primary hyperoxaluria type 1 (PH1), a severe, rare, inherited disorder of the liver.
News Boehringer's BLA for idarucizumab gets FDA priority review By PBR Staff Writer
The US Food and Drug Administration (FDA) has granted priority review for Boehringer Ingelheim Pharmaceuticals' biologics license application (BLA) for idarucizumab.
News Axxess signs manufacturing, marketing and distribution deal with Tong By PBR Staff Writer
Axxess Pharma, a US-based provider of nutritional supplements and over-the-counter (OTC) remedies, has signed a long-term manufacturing, marketing and distribution agreement with 8E6Tong Private Company (Tong), a Singapore-registered company.
News
ThromboGenics begins evaluation of Jetrea to treat retinal vein occlusion By PBR Staff Writer
Belgium-based biopharmaceutical firm ThromboGenics has started evaluating Jetrea (ocriplasmin) as a potential treatment for retinal vein occlusion (RVO).
News Actavis introduces Avycaz in US to treat cIAI and cUTI By PBR Staff Writer
Irish pharmaceutical firm Actavis has launched Avycaz (ceftazidime-avibactam) in the US to treat adult patients with complicated intra-abdominal infections (cIAI) (in combination with metronidazole).
News MedImmune enters into immuno-oncology clinical trial deal with Juno Therapeutics By PBR Staff Writer
AstraZeneca's biologics research and development arm MedImmune has entered into collaboration with US-based biopharmaceutical firm Juno Therapeutics to conduct combination clinical trials in immuno-oncology.
News

Latest News and Insight by Sector

Production & Manufacturing

Boehringer's BLA for idarucizumab gets FDA priority review
By PBR Staff Writer
The US Food and Drug Administration (FDA) has granted priority review for Boehringer Ingelheim Pharmaceuticals' biologics license application (BLA) for idarucizumab.
News
Axxess signs manufacturing, marketing and distribution deal with Tong
By PBR Staff Writer
Axxess Pharma, a US-based provider of nutritional supplements and over-the-counter (OTC) remedies, has signed a long-term manufacturing, marketing and distribution agreement with 8E6Tong Private Company (Tong), a Singapore-registered company.
News

Drug Research

ThromboGenics begins evaluation of Jetrea to treat retinal vein occlusion
By PBR Staff Writer
Belgium-based biopharmaceutical firm ThromboGenics has started evaluating Jetrea (ocriplasmin) as a potential treatment for retinal vein occlusion (RVO).
News
Novo Nordisk launches Saxenda injection in US for weight management
By PBR Staff Writer
Novo Nordisk has launched Saxenda (liraglutide [rDNA origin] injection), the first glucagon-like peptide-1 (GLP-1) receptor agonist for weight management in adults, in the US.
News

Inward Investment

PPF Group acquires minority stake in Cytune Pharma
By PBR Staff Writer
PPF Group, in cooperation with SOTIO has completed acquisition of minority stake in French biotechnology firm Cytune Pharma.
News
Merck in talks to acquire Cubist Pharmaceuticals for nearly $8bn
By PBR Staff Writer
New Jersey-based drug giant Merck & Co is, reportedly, in talks over a potential acquisition of antibiotics maker Cubist Pharmaceuticals for more than $8bn.
News

Packaging

Catalent completes acquisition of Australia's Pharmapak
By PBR Staff Writer
US-based Catalent Pharma Solutions has strengthened its ability to provide integrated solutions to customers with the acquisition of Pharmapak Technologies, an Australian pharmaceutical packaging business.
News
MP Global Products introduces foam-free packaging for shipment of temperature sensitive pharmaceuticals
MP Global Thermal Packaging Products insulated protective mailers and box liners are specifically designed for temperature control and protection of mail order shipments of temperature sensitive pharma, pet meds, and natural and organic cosmetics.
News

Contract Research & Services

MedImmune enters into immuno-oncology clinical trial deal with Juno Therapeutics
By PBR Staff Writer
AstraZeneca's biologics research and development arm MedImmune has entered into collaboration with US-based biopharmaceutical firm Juno Therapeutics to conduct combination clinical trials in immuno-oncology.
News
Triphase begins Phase I trial of marizomib-bevacizumab combination to treat glioblastoma
By PBR Staff Writer
Canada-based Triphase Accelerator has started a Phase I proof-of-concept clinical trial of marizomib, a highly potent proteasome inhibitor, for the treatment of patients with glioblastoma, the most common and aggressive malignant primary brain tumor.
News

Automation

Dicerna gets FDA orphan drug status for DCR-PH1 to treat primary hyperoxaluria type 1
By PBR Staff Writer
Dicerna Pharmaceuticals has received orphan drug designation from the US Food and Drug Administration (FDA) for its therapeutic candidate, DCR-PH1, to treat primary hyperoxaluria type 1 (PH1), a severe, rare, inherited disorder of the liver.
News
Oasmia's Paclical cancer drug gets Russian marketing approval
By PBR Staff Writer
Sweden-based Oasmia Pharmaceutical has received market authorization from the Russian Ministry of Health for its lead cancer product Paclical in Russia.
News

Regulatory Affairs

CanTx gets FDA orphan drug designation for Cantrixil to treat ovarian cancer
By PBR Staff Writer
CanTx, the Novogen-Yale joint venture, has received orphan drug designation from the US Food and Drug Administration (FDA) for its chemotherapy candidate drug, Cantrixil, to treat ovarian cancer.
News
CymaBay gets FDA orphan drug status for MBX-8025 to treat hypertriglyceridemia
By PBR Staff Writer
US-based biopharmaceutical firm CymaBay Therapeutics has received orphan drug designation from the US Food and Drug Administration (FDA) for MBX-8025 to treat patients with hyperlipoproteinemia types I or V (Fredrickson classification).
News



Data-Label.co.uk DataLabel have been supplying
the medical industry with labels
for over 10 years

Manufactures of
healthcare packaging
machinery